## Paul E M Fine

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6531567/publications.pdf Version: 2024-02-01



DALLE F. M. FINE

#	Article	IF	CITATIONS
1	The seroprevalence, waning rate, and protective duration of anti-diphtheria toxoid IgG antibody in Nha Trang, Vietnam. International Journal of Infectious Diseases, 2022, 116, 273-280.	3.3	5
2	The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi. Lancet Infectious Diseases, The, 2021, 21, 1590-1597.	9.1	21
3	P09â€ <b>Estimation of the causal effect of church attendance on risk of</b> <i> Mycobacterium tuberculosis</i> <b> infection in young children in rural Malawi using targeted maximum likelihood estimation</b> ., 2021, , .		0
4	BCG re-vaccination in Malawi: 30-year follow-up of a large, randomised, double-blind, placebo-controlled trial. The Lancet Global Health, 2021, 9, e1451-e1459.	6.3	15
5	The challenges of informative wastewater sampling for SARS-CoV-2 must be met: lessons from polio eradication. Lancet Microbe, The, 2020, 1, e189-e190.	7.3	47
6	Autochthonous leprosy in Spain: Has the transmission of MycobacteriumÂleprae stopped?. PLoS Neglected Tropical Diseases, 2020, 14, e0008611.	3.0	4
7	Human monkeypox – After 40Âyears, an unintended consequence of smallpox eradication. Vaccine, 2020, 38, 5077-5081.	3.8	207
8	Can ITN distribution policies increase children's ITN use? A DHS analysis. Malaria Journal, 2019, 18, 191.	2.3	9
9	Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. The Lancet Global Health, 2019, 7, e1541-e1552.	6.3	46
10	Relatedness of the incidence decay with exponential adjustment (IDEA) model, "Farr's law―and SIR compartmental difference equation models. Infectious Disease Modelling, 2018, 3, 1-12.	1.9	14
11	The duration of protection of school-aged BCG vaccination in England: a population-based case–control study. International Journal of Epidemiology, 2018, 47, 193-201.	1.9	41
12	Prevalence and risk factors for anemia severity and type in Malawian men and women: urban and rural differences. Population Health Metrics, 2017, 15, 12.	2.7	71
13	Impact of foot-and-mouth disease on milk production on a large-scale dairy farm in Kenya. Preventive Veterinary Medicine, 2015, 120, 177-186.	1.9	34
14	The decline of leprosy in the Republic of Korea; patterns and trends 1977-2013. Leprosy Review, 2015, 86, 316-27.	0.3	14
15	The Effects of School Holidays on Transmission of Varicella Zoster Virus, England and Wales, 1967–2008. PLoS ONE, 2014, 9, e99762.	2.5	22
16	Reply to Kernodle and von Reyn. Clinical Infectious Diseases, 2014, 59, 608-609.	5.8	2
17	John Snow's legacy: epidemiology without borders. Lancet, The, 2013, 381, 1302-1311.	13.7	34
18	Patterns and trends of leprosy in Mexico: 1989-2009. Leprosy Review, 2012, 83, 184-94.	0.3	16

PAUL E M FINE

#	Article	IF	CITATIONS
19	"Herd Immunity": A Rough Guide. Clinical Infectious Diseases, 2011, 52, 911-916.	5.8	891
20	Non-specific effects of vaccines: in context. Archives of Disease in Childhood, 2010, 95, 661-661.	1.9	5
21	Epidemiological studies of the â€~nonâ€specific effects' of vaccines: I – data collection in observational studies. Tropical Medicine and International Health, 2009, 14, 969-976.	2.3	25
22	The decline of leprosy in Japan: patterns and trends 1964–2008. Leprosy Review, 2009, 80, 432-440.	0.3	22
23	The decline of leprosy in Japan: patterns and trends 1964-2008. Leprosy Review, 2009, 80, 432-40.	0.3	10
24	Implication of new WHO growth standards on estimated prevalence and identification of early risk factors for malnutrition in rural Malawian infants. FASEB Journal, 2008, 22, 299.4.	0.5	0
25	10. The spread of bacterial infection, the problem of herd immunity Topley WWC, Wilson GS. J Hyg 1923; <b>21</b> : 243–249. Epidemiology and Infection, 2005, 133, S35-S36.	2.1	2
26	Poliomyelitis: very small risks and very large risks. Lancet Neurology, The, 2004, 3, 703.	10.2	7
27	Commentary: Is It Really M. leprae?1. International Journal of Leprosy and Other Mycobacterial Diseases, 2004, 72, 317.	0.3	1
28	Polio control after certification: major issues outstanding. Bulletin of the World Health Organization, 2004, 82, 47-52.	3.3	24
29	The Interval between Successive Cases of an Infectious Disease. American Journal of Epidemiology, 2003, 158, 1039-1047.	3.4	237
30	Commentary: Non-specific effects of measles vaccine—more grist for the mill. International Journal of Epidemiology, 2003, 32, 116-117.	1.9	4
31	BCG: The Challenge Continues. Scandinavian Journal of Infectious Diseases, 2001, 33, 243-245.	1.5	106
32	Patterns and Implications of Naturally Acquired Immune Responses to Environmental and Tuberculous Mycobacterial Antigens in Northern Malawi. Journal of Infectious Diseases, 2001, 184, 322-329.	4.0	106
33	Vaccines, Genes and Trials. Novartis Foundation Symposium, 1998, 217, 57-72.	1.1	21
34	LEPROSY: THE EPIDEMIOLOGY OF A SLOW BACTERIUM. Epidemiologic Reviews, 1982, 4, 161-188.	3.5	157
35	A possible mechanism for antibiotic-induced blood dyscrasias. International Journal of Laboratory Hematology, 1979, 1, 147-149.	0.2	0
36	Quantitative studies on the transmission ofParahistomonas wenrichiby ova ofHeterakis gallinarum. Parasitology, 1975, 70, 407-417.	1.5	13

#	Article	IF	CITATIONS
37	Quantitative studies on <i>Heterakis gallinarum</i> infections in the common fowl, <i>Gallus gallus L.</i> . Journal of Helminthology, 1975, 49, 229-244.	1.0	6

The BCG Experience: Implications for Future Vaccines against Tuberculosis. , 0, , 531-557.

134